CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 15 No. 2
 

Declines in Lung Cancer Rates—California, 1988-1997

February 1, 2001

Cigarette smoking is the leading cause of lung and bronchus cancer. During 1988-1997, per capita cigarette smoking in California declined more than twice as rapidly as it did in the rest of the country. To characterize lung cancer incidence in California, data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program were compared with data from the population-based California Cancer Registry. This report summarizes the results of that analysis, which indicated that during 1988-1997, age-adjusted lung cancer incidence rates in California declined significantly, compared with stable incidence rates for the combined SEER area of five states and three metropolitan areas.

The SEER data used in the analysis were from Connecticut, Hawaii, Iowa, New Mexico, and Utah, as well as Atlanta, Detroit, and the Seattle-Puget Sound area. The SEER registries in California were excluded from the SEER analysis and were included with the California Cancer Registry data. (California Cancer Registry data were statewide; the SEER data collected in California included Los Angeles and the San Francisco Bay area only.)

Cancer incidence rates were age-adjusted by the direct method based on estimated 2000 US population data. Annual lung and bronchus cancer incidence rates per 100,000 population during 1988-1997 were reported among men, women, and both sexes combined for California and the eight SEER regions combined (Table 1). Two measures of change were reported. First, the estimated annual percentage change (EAPC) was calculated using the average percentage increase or decrease in cancer incidence rates per year during 1988-1997, and a regression line was fitted using the assumption that the natural logarithm of cancer rates changed at a constant rate during the 10-year period. Second, the total percentage change was the average of 1988 and 1989 data minus the average of 1996 and 1997 data divided by 1988 and 1989 data and multiplied by 100. Statistical significance was set at alpha = .01 (Figure 1).

Non-California SEER data did not reveal a consistent pattern in the age-adjusted lung and bronchus cancer incidence rates during 1988-1997. An EAPC of -0.4% per year was not significantly different from 0. Comparing the California Cancer Registry incidence rates with non-California SEER incidence rates, the California lung and bronchus cancer incidence rates were slightly higher during 1988-1990 (Table 1). However, during 1991-1997, incidence rates in California declined from 68.0 per 100,000 to 60.1. During 1988-1997, overall lung and bronchus cancer California incidence rates decreased an average of 1.9% per year (P < .01, Figure 1). The California incidence rates decreased 14.0% during the 10-year period; the rates in non-California SEER regions decreased 2.7%.

The decline in incidence rates among men (all ages combined) in the California data was 1.5 times greater than the decline among men in the non-California SEER regions. Among men, lung and bronchus cancer incidence rates declined significantly during 1988-1997 in data from California and the SEER regions; however, the decline was greater in California (EAPC = -2.9%; P < .01) compared with non-California SEER regions (EAPC = -1.8%; P < .01). Among women (all ages combined) in California, lung and bronchus cancer incidence rates declined 4.8% during 1988-1997 (EAPC = -0.6; P < .01); incidence rates among women in non-California SEER regions increased 13.2% (EAPC = 1.5; P < .01).

Reported by: D.W. Cowling, PhD; S.L. Kwong, MPH; R. Schiag, MS; J.C. Lloyd, MA; D.G. Bal, MD; Tobacco Control Section and Cancer Surveillance Section; California Department of Health Services; Office on Smoking and Health; National Center for Chronic Disease Prevention and Health Promotion; Centers for Disease Control and Prevention (CDC).

Editorial Note From the CDC

More than 80% of lung and bronchus cancer is caused by cigarette smoking, and former smokers have about half the risk of dying from lung cancer than do current smokers. Compared with current smokers, the risk for lung and bronchus cancer among former smokers declines as the duration of abstinence lengthens, with risk reduction becoming evident within 5 years of cessation. Reductions in the smoking rate in a state could reduce lung and bronchus cancer rates within 5 years of the decline in smoking rates.

The difference in the rate of decline in lung and bronchus cancer incidence rates between California and other US regions may be related, in part, to the significant declines in smoking rates as a result of California tobacco control initiatives. The California Tobacco Control Program was created by Proposition 99 and was approved in 1988. The program emphasized a comprehensive approach to tobacco control, prevention, and education and included strategies to change social norms related to tobacco use.

The decrease in per capita cigarette consumption that began in 1990 has been attributed to the $0.25 increase in the excise tax in 1989. During 1988-1996, California had a more rapid decline in per capita cigarette consumption compared with the rest of the country. This decline has been attributed primarily to a change in the social acceptability of smoking among California residents. However, smoking rates in California were declining more rapidly than the rest of the country since the late 1980s, before enactment of Proposition 99.

Study Limitations

The findings in this study are subject to at least three limitations. First, the SEER cancer incidence rates are based on data from selected geographic areas and may not represent incidence rates nationally; SEER data in this analysis represent 9.5% of the US population (excluding California). Second, although a constant rate of change over the study period is the standard assumption when using the EAPC, this assumption has not been tested. Third, although decreased population smoking rates in California are probably responsible for reduced rates of lung and bronchus cancer, a cause-and-effort relation cannot be determined through population-based assessments.

Programs in Other States

Following the California model, aggressive and comprehensive tobacco-control programs have been implemented in other states, including Arizona, Florida, Maine, Massachusetts, and Oregon. Initial results from several states have shown substantial declines in per capita cigarette consumption and/or changes in the prevalence of adult or youth smoking rates. The results of this report suggest that a comprehensive tobacco prevention and education program may also reduce rates of lung and bronchus cancer.

On the basis of results from state programs, the CDC published the Best Practices for Comprehensive Tobacco Control. This document, along with the release of the Surgeon General’s Report, Reducing Tobacco Use: A Report of the Surgeon General, provides guidance to states in establishing successful and sustainable tobacco control programs.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
James B. Yu, MD1 , May 17, 2013

A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Skin Lesions
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Colorectal Lesions
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Patient Quality of Life Endpoints in Oncology Trials, Part II
  • Who's Coding Whom?
  • “How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Conflicts of Interest in Medicine: What About Ties to Payers?
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy